What will the average number of measles cases be during Trump's term?
I assess a 70% probability that the market's 'Yes' outcome occurs — the very large 2026 measles burden (1,952 confirmed as of May 21) creates a high baseline that makes a high multi-year average considerably more likely than markets currently price.
Analysis
**Stage 1 — Blind analysis (ignore market price):**
- *Key observed fact:* the CDC reports 1,952 confirmed U.S. measles cases as of May 21, 2026, with cases reported from 40 jurisdictions. That is already far above the norm for recent years and constitutes a very large early-term accumulation.
- *Why a single-year spike matters:* the question asks for a time-average over the four-year span 2025–2028. A single very large outbreak year (here, 2026) can materially raise that four-year mean. If 2026 finishes anywhere near the current pace (2,000+), the term average will be driven upward unless the other three years are close to zero — an unlikely symmetrical outcome given the dynamics of measles transmission and immunity gaps.
- *Transmission and outbreak persistence factors:* measles is extremely transmissible; where pockets of under-vaccinated people exist, clusters and multi-year transmission chains are common. The report of outbreaks across multiple jurisdictions indicates the current activity is not just isolated importation events but involves sustained local transmission in several places, which raises the chance of continued sizable annual counts in adjacent years.
- *Countervailing factors (blind):* high early-year totals can be compressed into a single anomalous year. Rapid, targeted public health responses (large vaccination campaigns, school exclusions, heightened surveillance) historically have curtailed measles outbreaks within 1–2 seasons in many settings. Waning importation pressure and re-prioritization of immunization efforts could push 2027–2028 back toward recent low baselines.
- *Net assessment (Stage 1):* weighing the strong upward pull from an already-large 2026 and the plausibility of public-health containment, I estimate a substantially greater-than-even chance that the four-year average ends up on the higher side of historical norms. My independent probability for the 'Yes' outcome is 70%.
**Stage 2 — Market calibration (considering current market prices):**
- *Market state:* Yes priced ~0.31, No ~0.69, with substantial volume (~146k contracts). Markets are betting the 'Yes' outcome is unlikely.
- *Why the market might be underpricing Yes:* traders may be treating the current 2026 spike as an ephemeral blip that will be diluted by three lower years (2025, 2027, 2028). They might also be anchoring to long-term low measles incidence in the immediate post-COVID years and under-weighting the outsized influence of a single ~2k-count year on a four-year average. Additionally, ambiguity about the exact threshold that defines the binary question could lead market conservatism (traders require stronger evidence to buy Yes).
- *Why the market might be correct or fairly priced:* sophisticated traders may believe the current high 2026 count will be aggressively countered by large-scale vaccination and containment, producing 2027–2028 totals low enough to keep the four-year average below the threshold. Market participants may also have private information about policy responses, vaccination campaigns, or changes in case definitions that reduce the chance of a high-term average.
- *Calibration conclusion:* given the extremely high 2026 baseline and the mathematical leverage one large year has on a four-year mean, the market's 31% for Yes looks too low in my view. Unless there is strong reason to expect near-zero measles in the three other years (which I view as unlikely), a higher probability is justified. Therefore I maintain a 70% independent probability and see the market as underpricing the risk that 2026's outbreak drives the multi-year average high.
Arguments
For
- The 2026 baseline is already very large (1,952 by May 21); a completed 2026 total near or above ~2,000 exerts a strong upward influence on the 4‑year average.
- Outbreaks reported across 40 jurisdictions and multiple clusters suggest widespread vulnerability rather than isolated importations — these conditions favor persistence into subsequent years.
- Measles has very high R0; in under-vaccinated pockets, outbreaks can reignite and propagate year-to-year, making a multi-year elevated average plausible.
- Political and policy changes that reduce public-health messaging or vaccine acceptance can maintain higher incidence levels across multiple years.
Against
- Historically, intensive public-health intervention and focused vaccination can and do extinguish outbreaks within 1–2 seasons, which would pull the multi-year average down.
- The large early 2026 count could be an anomaly driven by specific, addressable clusters; if containment succeeds the remaining years could revert to low counts.
- If importations decrease and community immunity rebounds, measles incidence can return to the low pre‑outbreak baseline rapidly.
- Market participants may have information about upcoming large vaccination drives, policy shifts, or funding that significantly reduce future cases — possibilities that would favor a No outcome.
Key drivers
- Magnitude of the 2026 outbreak (1,952 confirmed as of May 21) and final 2026 total.
- Effectiveness and scale of public-health responses (vaccination campaigns, school policies, outbreak control).
- Geographic spread and concentration of immunity gaps (pockets of low MMR coverage across jurisdictions).
- Importation pressure and international measles activity during 2025–2028.
Risk factors
- Rapid, effective outbreak control leading to sharp declines after 2026 (pushes average down).
- Improved vaccination uptake in response to the 2026 outbreak (reduces future years' cases).
- Underreporting or changes to surveillance/case definitions that alter official counts (could bias observed totals).
- Seasonality and stochastic extinction: measles transmission can stop quickly in some settings if chains burn out.
Scenarios
Best case
Yes best-case: 2026 ends as a multi-thousand-case national outbreak (2,000–5,000). 2025 and 2027–2028 remain moderately elevated (several hundred to a thousand each) because of sustained transmission across under-vaccinated pockets, producing a high four-year average well above recent norms.
Most likely
Most likely: 2026 finishes substantially above recent-year norms (final total around 2,000–3,000). 2025 was likely low or modest; 2027–2028 decline relative to 2026 but not to zero, producing a moderate-to-high four-year average — enough, in my judgment, to favor the Yes outcome but not so extreme as to be a multi-thousand-per-year sustained endemic state.
Worst case
No worst-case: the 2026 spike proves transitory. Aggressive, well-coordinated public-health responses and rapid local vaccination campaigns suppress transmission such that 2027–2028 return to very low counts, and the four-year mean falls below the market's threshold for a Yes outcome.
More from this day
- FinancialsKalshi13y
Will OpenAI or Anthropic IPO first?
AI70%MKT24%Edge+46Hidden GemI assess ~70% chance that OpenAI will IPO before Anthropic. OpenAI shows clearer preparatory work, stronger near-term monetization paths, and investor incentives to pursue a public listing sooner than Anthropic.
- PoliticsKalshi18y
Which G7 leader will leave next?
AI40%MKT78%Edge-38HypedI estimate a substantially lower chance than the market that the UK Prime Minister (Keir Starmer) will be the first G7 leader to leave; I put that probability at 40% and allocate the rest to other vulnerable leaders (Italy, France, Germany, Japan).
- EconomicsKalshi3y
Who will be the world's first trillionaire?
AI60%MKT97%Edge-37HypedI assess a better-than-even (but far from certain) chance that Elon Musk will be the world’s first trillionaire by Jan 1, 2030 — most likely driven by a high-valuation SpaceX float or re-rating, but significant execution, timing and tax risks remain.